DataMeds AI regains Nasdaq equity compliance
DataMeds may be subject to delisting if its next periodic report does not evidence compliance.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
DataMeds AI, Inc. (MEDS) regained compliance with Nasdaq Listing Rule 5550(b)(1) after receiving written notice from Nasdaq staff on October 19, 2026. The rule requires at least $2,500,000 in stockholders’ equity; DataMeds said an October 13 company filing confirmed equity exceeded that threshold, and an October 16 filing provided details of the material events that resulted in exceeding it.
Earlier, Nasdaq notified the company on April 13, 2026 that its annual report for the fiscal year ended December 31, 2025 reported stockholders’ equity of -$12,447,801, below the minimum, and that it did not meet the rule’s alternative market-value or net-income standards. Nasdaq notified the company on June 9, 2026 that it had regained bid-price compliance and granted additional time to meet the equity requirement. DataMeds said it may be subject to delisting if its next periodic report does not evidence compliance.
Insights
Analyzing...
8-K Event Classification
Key Figures
Key Terms
minimum stockholders’ equity requirement financial
alternative compliance standards regulatory
bid-price compliance regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
Did MEDS regain Nasdaq listing compliance?
Could MEDS still face delisting?
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM
CURRENT
REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act Of 1934
Date
of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
| (Address of Principal Executive Offices) | (Zip Code) |
Registrant’s
telephone number, including area code:
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
| The |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
Emerging
growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 7.01 Regulation FD Disclosure.
On October 20, 2026, DataMeds AI, Inc. (the “Company”) issued a press release announcing it has regained compliance with Nasdaq Listing Rule 5550(b)(1). The press release is attached to this Current Report on Form 8-K as Exhibit 99.1.
Item 8.01 Other Events.
As previously disclosed on Form 8-K/A filed on April 21, 2026, on April 13, 2026, the Company received a deficiency letter (the “Deficiency Letter”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, based on the stockholders’ equity of $(12,447,801) reported in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, the Company no longer satisfied the $2,500,000 minimum stockholders’ equity requirement for continued listing on The Nasdaq Capital Market set forth in Nasdaq Listing Rule 5550(b)(1), and that, as of the date of the Deficiency Letter, the Company also did not meet the alternative compliance standards under that Rule based on market value of listed securities or net income from continuing operations.
On October 19, 2026, the Company received written notice from the Staff informing the Company that it has regained compliance with Nasdaq Listing Rule 5550(b)(1).
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
| Exhibit No. | Description of Exhibit | |
| 99.1 | Press Release dated October 20, 2026 | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| DataMeds AI, Inc. | ||
| Date: October 20, 2026 | By: | /s/ Prashant Patel |
| Prashant Patel, President | ||
Exhibit 99.1
 |
PRESS RELEASE DATAMEDS AI, INC. (DBA DATAMEDS SI) 3000 BAYPORT DRIVE, SUITE 950 TAMPA, FLA. 33607 www.datamedsai.com
RUBENSTEIN PUBLIC RELATIONS CONTACT: JAMES LAMBERT 212-805-3024 JLAMBERT@RUBENSTEINPR.COM | |
| FOR IMMEDIATE RELEASE |
DATAMEDS REGAINS COMPLIANCE WITH NASDAQ LISTING STANDARDS
Tampa, Fla. – Tuesday, October 20, 2026 – DataMeds AI, Inc. (NASDAQ: MEDS) (“DataMeds AI,” “DataMEDS SI,” “DataMEDS,” or the “Company”), a healthcare company leveraging its Health IT and physical infrastructure together with its super intelligence (artificial intelligence) platform EinsteinRx™ and smart contracts platform PharmacyChain™, today announced that it has received a notification letter (the “Compliance Notice”) from the Listing Qualifications Staff of the Nasdaq Stock Market, LLC (“Nasdaq”) dated October 19, 2026, informing DataMEDS that it has regained compliance with Nasdaq Listing Rule 5550(b)(1) (the “Equity Rule”). In order to regain compliance with the Equity Rule, DataMEDS needed to have a minimum stockholders’ equity of $2.5 million.
The Company originally received a notice of delisting from NASDAQ on April 13, 2026 outlining the basis for delisting proceedings:
| 1) | Failure to meet minimum $1.00 bid-price; and |
| 2) | Failure to maintain a minimum of $2,500,000 in stockholder’s equity. |
NASDAQ notified the Company on June 9, 2026 that it had regained bid-price compliance and provided the Company additional time to attempt to regain compliance with the minimum stockholders’ equity requirement.
Based on a Company Form 8-K filing on October 13, 2026 that confirmed the Company’s stockholder’s equity exceeded $2,500,000 and a subsequent Form 8-K filing on October 16, 2026 that provided additional details on the material events that resulted in the Company exceeding $2,500,000 in stockholders’ equity, on October 19, 2026 NASDAQ confirmed that the Company was in compliance with the Equity Rule. If the Company fails to evidence compliance upon filing its next periodic report it may be subject to delisting.
For more information, visit www.datamedsai.com or contact James Lambert, Vice President at Rubenstein Public Relations, at jlambert@rubensteinpr.com or at 212-805-3024.
| -1- |
About DataMeds AI, Inc. (DBA DataMeds SI)
DataMeds SI (NASDAQ: MEDS) is a healthcare company that focuses on the vertical integration of technology, pharmacy, pharmaceutical-adjacent and telemedicine business units through its Health IT platforms to deliver a better experience for consumers and providers. Headquartered in Tampa, Fla., DataMEDS incorporates the super intelligence platform EinsteinRx™ and blockchain-enabled smart contracts platform PharmacyChain™ into the Health Lives Here mobile application, and its Corexa Pharmacy provides pharmacy dispensing and related services, including the distribution of products developed by Tollo Health. DataMEDS has licensed patented GLP-1 patient management technology from REBOOT, a subsidiary of Data Health Partners. The Company’s Helomics Corporation subsidiary operates a CLIA-certified laboratory in Pittsburgh offering the ChemoFx® Assay.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based on management’s current expectations and are not predictions of actual performance. Forward-looking statements include, without limitation, the Company’s anticipated business strategy, operating plans and growth opportunities; the Company’s ability to maintain compliance with Nasdaq listing standards; the Company’s liquidity, capital resources and ability to fund operations; the Company’s ability to maintain compliance with Nasdaq listing standards, the development of a proprietary blockchain and the development of provider-network features, the creation of the Health Lives Here pharmacy network, the success of the NFL Alumni Health partnership, the companies’ proposed transaction with DataVault AI Inc. (NASDAQ: DVLT), Scilex Holding Company, EOS Holdings and HealthBridge Advisors (controlling shareholder of Tollo Health, LLC); the satisfaction or waiver of closing conditions applicable to any of the foregoing; the receipt of stockholder approval and any other required approvals; the Company’s anticipated business strategy, operating plans and growth opportunities; the integration of telemedicine, pharmacy, laboratory, wearable-device, artificial intelligence, blockchain and data-management technologies; the proposed development, commercialization and expansion of EinsteinRx AI, PharmacyChain, Health Lives Here and related platforms; the anticipated growth of the market for Long COVID products and related treatment approaches; the companies’ ability to empower patients to access, manage, control or monetize health data; the anticipated benefits of the companies’ technology platforms, strategic relationships and business combinations; the Company’s capitalization, outstanding securities, lock-up arrangements, public float and registration statements. Actual results may differ materially from those expressed or implied in these forward-looking statements due to a number of risks and uncertainties, including those described under “Risk Factors” in the Company’s most recent Annual Report on Form 10-K and subsequent filings with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to update or revise any forward-looking statements, except as required by law.
DataMeds AI Media Contact
James Lambert, Vice President
Rubenstein Public Relations
Phone: 212.805.3024
Email: jlambert@rubensteinpr.com
DataMeds AI Investor Contact
Investor Relations: IR@datamedsai.com
###
| -2- |